Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6565)	6/23/1998 10:21:00 PM
From: Tharos	Read Replies (2) \| Respond to of 17367

I think Xoma is throwing up a smoke screen. If I had not been fortunate enough to have a contact in the UK we still would not have the information about a clinical trial underway in the UK. This trial has a two edged potential: 1) if trail fails and word gets out, stock could tumble and we would have no indication as to why. 2. if trail is successful, it could be that final straw needed to convince a fund manager to buy and we could be locked out of the opportunity to adjust our stock holdings based on the knowledge of the program's existence. Add to that this little tid-bit: 3. front office has knowledge of new clinical trial starting, CFO buys more stock in company before word is released. We have been polite about it so far. This is a serious matter. Companies have been taken to task by regulatory agencies for much less.